Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Levocetirizine is a third-generation antihistamine and the R-enantiomer of cetirizine. It acts as a selective histamine H1 receptor antagonist, blocking the effects of histamine—a chemical responsible for allergic symptoms such as itching, sneezing, runny nose, watery eyes, and hives. By inhibiting the H1 receptor on mast cells and basophils, levocetirizine prevents IgE-mediated release of histamine and reduces allergy symptoms. It is primarily indicated for the relief of symptoms associated with allergic rhinitis (hay fever), both seasonal and perennial types, as well as chronic idiopathic urticaria (hives). Levocetirizine is available in oral tablet and solution forms[1][2][3][4][5][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on levocetirizine.